Unusual 11 Mid-Day Movers 01/28: (KERX) (FURX) (BLRX) Higher; (RPRX) (JOSB) (JVA) Lower
Tweet
Share
E-mail
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 64.4% HIGHER; announced successful top-line results from the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint. For more color, click here.
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) 50.6% HIGHER; confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Under its agreement with Takeda, Furiex is entitled to receive a $25 million milestone payment as a result of this approval, as well as royalties on sales in the United States and potential sales-based milestones
Repros Therapeutics Inc. (Nasdaq: RPRX) 27.9% LOWER; provided a revised date for expected clinical results from the first pivotal study, ZA-301, of Androxal in the treatment of secondary hypogonadism. The Company now plans to provide the data in Q3 2013 instead of Q2 2013. Click here for more color.
JoS. A. Bank Clothiers, Inc. (Nasdaq: JOSB) 17.6% LOWER; announced that net income for fiscal year 2012 is expected to be approximately 20% lower than net income for fiscal year 2011. Actual results will depend on, among other things, sales for the remainder of the year, expenses and normal year-end processing. Fiscal year 2012 is a 53-week year which will end February 2, 2013; fiscal year 2011 was a 52 week year which ended January 28, 2012.
Coffee Holding Co. (Nasdaq: JVA) 12.0% LOWER; reports FY12 sales of $173.66 million, from $146.76 million in FY11. Net income was 37 cents per share, from 14 cents the prior year. Gross margins improved 1 point to 6.8 percent.
BioLineRx Ltd. (Nasdaq: BLRX) 11.7% HIGHER; entered into an agreement (the “Agreement”) with Biokine Therapeutics Ltd. to in-license the rights to BL-8040 for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor.
RadioShack Corp. (NYSE: RSH) 11.7% HIGHER; moving higher as BB&T Capital upgraded peer Best Buy (NYSE: BBY) to Buy earlier.
3D Systems (NYSE: DDD) 11.0% LOWER; no hard news out on 3D Systems today, but shares might be in store for a slight pullback following months upon months of share appreciation.
OCZ Technology Group, Inc. (Nasdaq: OCZ) 10.9% HIGHER; announced that it has added 750W and 850W power supply unit (PSU) models to the award-winning Silencer Mk III Power Supply Series from PC Power & Cooling. With these new high-wattage options, the Silencer Mk III provides a professional-grade power solution rated for industrial usage and provides the performance and stability required for demanding computing environments.
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 9.3% HIGHER; announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- of Johnson & Johnson (NYSE: JNJ) -- for the clinical development of all-oral direct-acting antiviral (DAA) HCV combination therapies. The collaboration will evaluate combinations including IDX719, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen and Medivir AB, and TMC647055, a once-daily non-nucleoside polymerase inhibitor, boosted with low dose ritonavir, being developed by Janssen.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) 50.6% HIGHER; confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Under its agreement with Takeda, Furiex is entitled to receive a $25 million milestone payment as a result of this approval, as well as royalties on sales in the United States and potential sales-based milestones
Repros Therapeutics Inc. (Nasdaq: RPRX) 27.9% LOWER; provided a revised date for expected clinical results from the first pivotal study, ZA-301, of Androxal in the treatment of secondary hypogonadism. The Company now plans to provide the data in Q3 2013 instead of Q2 2013. Click here for more color.
JoS. A. Bank Clothiers, Inc. (Nasdaq: JOSB) 17.6% LOWER; announced that net income for fiscal year 2012 is expected to be approximately 20% lower than net income for fiscal year 2011. Actual results will depend on, among other things, sales for the remainder of the year, expenses and normal year-end processing. Fiscal year 2012 is a 53-week year which will end February 2, 2013; fiscal year 2011 was a 52 week year which ended January 28, 2012.
Coffee Holding Co. (Nasdaq: JVA) 12.0% LOWER; reports FY12 sales of $173.66 million, from $146.76 million in FY11. Net income was 37 cents per share, from 14 cents the prior year. Gross margins improved 1 point to 6.8 percent.
BioLineRx Ltd. (Nasdaq: BLRX) 11.7% HIGHER; entered into an agreement (the “Agreement”) with Biokine Therapeutics Ltd. to in-license the rights to BL-8040 for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor.
RadioShack Corp. (NYSE: RSH) 11.7% HIGHER; moving higher as BB&T Capital upgraded peer Best Buy (NYSE: BBY) to Buy earlier.
3D Systems (NYSE: DDD) 11.0% LOWER; no hard news out on 3D Systems today, but shares might be in store for a slight pullback following months upon months of share appreciation.
OCZ Technology Group, Inc. (Nasdaq: OCZ) 10.9% HIGHER; announced that it has added 750W and 850W power supply unit (PSU) models to the award-winning Silencer Mk III Power Supply Series from PC Power & Cooling. With these new high-wattage options, the Silencer Mk III provides a professional-grade power solution rated for industrial usage and provides the performance and stability required for demanding computing environments.
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 9.3% HIGHER; announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- of Johnson & Johnson (NYSE: JNJ) -- for the clinical development of all-oral direct-acting antiviral (DAA) HCV combination therapies. The collaboration will evaluate combinations including IDX719, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen and Medivir AB, and TMC647055, a once-daily non-nucleoside polymerase inhibitor, boosted with low dose ritonavir, being developed by Janssen.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Create E-mail Alert Related Categories
Special ReportsRelated Entities
BB&T Capital Markets, Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
